Bladder cancer risk from occupational and environmental exposures

Urologic Oncology: Seminars and Original Investigations

Volumn 30, Issue 2, 2012, Pages 199-211

  Kiriluk, Kyle J ^a   Prasad, Sandip M ^a   Patel, Amit R ^a   Steinberg, Gary D ^a   Smith, Norm D ^a  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

Bladder cancer; Environment; Epidemiology; Etiology; Risk factors

Indexed keywords

ANALGESIC AGENT; ARISTOLOCHIA FANGCHI EXTRACT; AROMATIC AMINE; ARSENIC ACID DERIVATIVE; CHLORINE; HALOGENATED HYDROCARBON; NITRATE; NITRITE; OXAZAPHOSPHORINE DERIVATIVE; PHENACETIN; PIOGLITAZONE; POLYCYCLIC AROMATIC HYDROCARBON; REACTIVE OXYGEN METABOLITE; SWEETENING AGENT; VITAMIN D; WATER;

BLADDER CANCER; CANCER EPIDEMIOLOGY; CANCER GROWTH; CANCER INCIDENCE; CANCER MORTALITY; CANCER RISK; CARCINOGENESIS; CHEMICAL STRUCTURE; CHRONIC INFLAMMATION; CIGARETTE SMOKING; CYSTITIS; DRUG METABOLISM; DRUG USE; ENVIRONMENTAL EXPOSURE; GENETIC VARIABILITY; GENETICS; HEALTH CARE ACCESS; HUMAN; IMMUNE DEFICIENCY; IMMUNE SYSTEM; IONIZING RADIATION; OCCUPATIONAL EXPOSURE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SCHISTOSOMA HEMATOBIUM; WART VIRUS; WATER ANALYSIS;

ENVIRONMENTAL EXPOSURE; HUMANS; OCCUPATIONAL EXPOSURE; RISK FACTORS; URINARY BLADDER NEOPLASMS;

EID: 84857546743     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2011.10.010     Document Type: Review

References (156)

1. Cancer Facts and Figures 2011 2011, American Cancer Society, American Cancer Society, Atlanta.
2. Lopez-Beltran A., Sauter G., Gasser T., et al. Infiltrating urothelial carcinoma. World Health Organization Classification of Tumours Pathology and Genetics of Tumours of the Urinary System and Male Genital System 2004, Vol 7:93-109. IARC Press, Lyon, France. 1st ed.
3. Dietrich H., Dietrich B. Ludwig Rehn (1849-1930). Pioneering findings on the aetiology of bladder tumors. World J Urol 2001, 19:151-153.
4. McCullough D.L., Lamma D.L., McLaughlin A.P., et al. Familial transitional cell carcinoma of the bladder. J Urol 1975, 113:629-635.
5. Lynch H.T., Kimberling W.J., Lynch J.F., et al. Familial bladder cancer in an oncology clinic. Cancer Genet Cytogenet 1987, 27:161-165.
6. Kiemeney L.A., Schoenberg M. Familial transitional cell carcinoma. J Urol 1996, 156:867-872.
7. Mousavi S.M., Sundquist J., Hemminki K. Risk of transitional-cell carcinoma of the bladder in first- and second-generation immigrants to Sweden. Eur J Cancer Prev 2010, 19:275-279.
8. Kiemeney L.A., Moret N.C., Witjes J.A., et al. Familial transitional cell carcinoma among the population of Iceland. J Urol 1997, 157:1649-1651.
9. Aben K.K.H., Baglietto L., Baffoe-Bonnie A., et al. Segregation analysis of urothelial cell carcinoma. Eur J Cancer 2006, 42:1428-1433.
10. Volanis D., Kadiyska T., Galanis A., et al. Environmental factors and genetic susceptibility promote urinary bladder cancer. Toxicol Lett 2010, 193:131-137.
11. Horikawa Y., Gu J., Wu X. Genetic susceptibility to bladder cancer with an emphasis on gene-gene and gene-environmental interactions. Curr Opin Urol 2008, 18:493-498.
12. Burch J.D., Rohan T.E., Howe G.R., et al. Risk of bladder cancer by source and type of tobacco exposure: A case-control study. Int J Cancer 1989, 44:622-628.
13. Zeegers M.P., Tan F.E., Dorant E., et al. The impact of characteristics of cigarette smoking on urinary tract cancer risk: A meta-analysis of epidemiologic studies. Cancer 2000, 89:630-639.
14. Holsti L.R., Ermala P. Papillary carcinoma of the bladder in mice, obtained after peroral administration of tobacco tar. Cancer 1955, 8:679-682.
15. Lilienfeld A.M. The relationship of bladder cancer to smoking. Am J Public Health Nations Health 1964, 54:1864-1875.
16. The Health Consequences of Smoking: A Report of the Surgeon General 2004, U.S. Department of Health and Human Services, U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, Atlanta, GA.
17. Fortuny J., Kogevinas M., Chang-Claude J., et al. Tobacco, occupation and non-transitional-cell carcinoma of the bladder: An international case-control study. Int J Cancer 1999, 80:44-46.
18. Kantor A.F., Hartge P., Hoover R.N., et al. Epidemiological characteristics of squamous cell carcinoma and adenocarcinoma of the bladder. Cancer Res 1988, 48:3853-3855.
19. Strope S.A., Montie J.E. The causal role of cigarette smoking in bladder cancer initiation and progression, and the role of urologists in smoking cessation. J Urol 2008, 180:31-37. Discussion 37.
20. Brennan P., Bogillot O., Cordier S., et al. Cigarette smoking and bladder cancer in men: A pooled analysis of 11 case-control studies. Int J Cancer 2000, 86:289-294.
21. Fleshner N., Garland J., Moadel A., et al. Influence of smoking status on the disease-related outcomes of patients with tobacco-associated superficial transitional cell carcinoma of the bladder. Cancer 1999, 86:2337-2345.
22. Chen C.-H., Shun C.-T., Huang K.-H., et al. Stopping smoking might reduce tumor recurrence in non-muscle-invasive bladder cancer. BJU Int 2007, 100:281-286. Discussion 286.
23. Wilhelm-Benartzi C.S., Christensen B.C., Koestler D.C., et al. Association of secondhand smoke exposures with DNA methylation in bladder carcinomas. Cancer Causes Control 2011, 22:1205-1213.
24. McCormack V.A., Agudo A., Dahm C.C., et al. Cigar and pipe smoking and cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC). Int J Cancer 2010, 127:2402-2411.
25. Pitard A., Brennan P., Clavel J., et al. Cigar, pipe, and cigarette smoking and bladder cancer risk in European men. Cancer Causes Control 2001, 12:551-556.
26. Alberg A.J., Kouzis A., Genkinger J.M., et al. A prospective cohort study of bladder cancer risk in relation to active cigarette smoking and household exposure to secondhand cigarette smoke. Am J Epidemiol 2007, 165:660-666.
27. Van Hemelrijck M.J.J., Michaud D.S., Connolly G.N., et al. Secondhand smoking, 4-aminobiphenyl, and bladder cancer: Two meta-analyses. Cancer Epidemiol. Biomarkers Prev 2009, 18:1312-1320.
28. Zeegers M.P.A., Goldbohm R.A., van den Brandt P.A. A prospective study on active and environmental tobacco smoking and bladder cancer risk (The Netherlands). Cancer Causes Control 2002, 13:83-90.
29. Jiang X., Yuan J.-M., Skipper P.L., et al. Environmental tobacco smoke and bladder cancer risk in never smokers of Los Angeles County. Cancer Res 2007, 67:7540-7545.
30. Hammond S.K., Coghlin J., Gann P.H., et al. Relationship between environmental tobacco smoke exposure and carcinogen-hemoglobin adduct levels in nonsmokers. J Natl Cancer Inst 1993, 85:474-478.
31. Schorp M.K., Leyden D.E. Biomonitoring of smoke constituents: Exposure to 4-aminobiphenyl and 4-aminobiphenyl hemoglobin adduct levels in nonsmokers and smokers. Inhal Toxicol 2010, 22:725-737.
32. How Tobacco Smoke Causes Disease: The Biology and Behavioral Basis for Smoking-Attributable Disease: A Report of the Surgeon General 2010, U.S. Department of Health and Human Services, U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, Atlanta, GA.
33. Alberg A.J., Hébert J.R. Cigarette smoking and bladder cancer: A new twist in an old saga?. J. Natl Cancer Inst 2009, 101:1525-1526.
34. Hirao Y., Kim W.-J., Fujimoto K. Environmental factors promoting bladder cancer. Curr Opin Urol 2009, 19:494-499.
35. Tsukino H., Kuroda Y., Nakao H., et al. Cytochrome P450 (CYP) 1A2, sulfotransferase (SULT) 1A1, and N-acetyltransferase (NAT) 2 polymorphisms and susceptibility to urothelial cancer. J Cancer Res Clin Oncol 2004, 130:99-106.
36. Moore L.E., Baris D.R., Figueroa J.D., et al. GSTM1 null and NAT2 slow acetylation genotypes, smoking intensity and bladder cancer risk: Results from the New England bladder cancer study and NAT2 meta-analysis. Carcinogenesis 2011, 32:182-189.
37. Hein D.W. Molecular genetics and function of NAT1 and NAT2: Role in aromatic amine metabolism and carcinogenesis. Mutat Res 2002, 506:7507-7577.
38. Bell D.A., Taylor J.A., Paulson D.F., et al. Genetic risk and carcinogen exposure: A common inherited defect of the carcinogen-metabolism gene glutathione S-transferase M1 (GSTM1) that increases susceptibility to bladder cancer. J Natl Cancer Inst 1993, 85:1159-1164.
39. Hung R.J., Boffetta P., Brennan P., et al. GST, NAT, SULT1A1, CYP1B1 genetic polymorphisms, interactions with environmental exposures and bladder cancer risk in a high-risk population. Int J Cancer 2004, 110:598-604.
40. Aromatic Amines: An Assessment of the Biological and Environmental Effects 1981, Committee on Amines, Board on Toxicology and Environmental Health Hazards, Assembly of Life Sciences, National Research Council, National Academy Press, Washington, DC.
41. Bartsch H., Caporaso N., Coda M., et al. Carcinogen hemoglobin adducts, urinary mutagenicity, and metabolic phenotype in active and passive cigarette smokers. J Natl Cancer Inst 1990, 82:1826-1831.
42. Granella M., Priante E., Nardini B., et al. Excretion of mutagens, nicotine, and its metabolites in urine of cigarette smokers. Mutagenesis 1996, 11:207-211.
43. Case R.A., Hosker M.E., McDonald D.B., et al. Tumours of the urinary bladder in workmen engaged in the manufacture and use of certain dyestuff intermediates in the British chemical industry. I. The role of aniline, benzidine, &;α-naphthylamine, and β-naphthylamine. Br J Ind Med 1954, 11:75-104.
44. Carreón T., Hein M.J., Viet S.M., et al. Increased bladder cancer risk among workers exposed to o-toluidine and aniline: A reanalysis. Occup Environ Med 2010, 67:348-350.
45. Pira E., Piolatto G., Negri E., et al. Bladder cancer mortality of workers exposed to aromatic amines: A 58-year follow-up. J Natl Cancer Inst 2010, 102:1096-1099.
46. Ward E.M., Sabbioni G., DeBord D.G., et al. Monitoring of aromatic amine exposures in workers at a chemical plant with a known bladder cancer excess. J Natl Cancer Inst 1996, 88:1046-1052.
47. Dolin P.J. A descriptive study of occupation and bladder cancer in England and Wales. Br J Cancer 1992, 65:476-478.
48. Viel J.F., Challier B. Bladder cancer among French farmers: Does exposure to pesticides in vineyards play a part?. Occup Environ Med 1995, 52:587-592.
49. Budnick L.D., Logue J.N., Sokal D.C., et al. Cancer and birth defects near the Drake Superfund site, Pennsylvania. Arch Environ Health 1984, 39:409-413.
50. Cassidy L.D., Youk A.O., Marsh G.M. The Drake Health Registry Study: Cause-specific mortality experience of workers potentially exposed to beta-naphthylamine. Am J Ind Med 2003, 44:282-290.
51. Freudenthal R.I., Anderson D.P. A re-examination of the cause of excess bladder cancers in chemical plant workers. J Natl Cancer Inst 1994, 86:59-62.
52. Case R.A., Pearson J.T. Tumours of the urinary bladder in workmen engaged in the manufacture and use of certain dyestuff intermediates in the British chemical industry. II. Further consideration of the role of aniline and of the manufacture of auramine and magenta (fuchsine) as possible causative agents. Br J Ind Med 1954, 11:213-216.
53. Melick W.F., Escue H.M., Naryka J.J., et al. The first reported cases of human bladder tumors due to a new carcinogen-xenylamine. J Urol 1955, 74:760-766.
54. Baan R., Straif K., Grosse Y., et al. Carcinogenicity of some aromatic amines, organic dyes, and related exposures. Lancet Oncol 2008, 9:322-323.
55. Swaminathan S., Frederickson S.M., Hatcher J.F., et al. Neoplastic transformation and DNA-binding of 4,4'-methylenebis(2-chloroaniline) in SV40-immortalized human uroepithelial cell lines. Carcinogenesis 1996, 17:857-864.
56. Harling M., Schablon A., Schedlbauer G., et al. Bladder cancer among hairdressers: Ameta-analysis. Occup Environ Med 2010, 67:351-358.
57. Takkouche B., Regueira-Méndez C., Montes-Martínez A. Risk of cancer among hairdressers and related workers: A meta-analysis. Int J Epidemiol 2009, 38:1512-1531.
58. Koutros S., Silverman D.T., Baris D., et al. Hair dye use and risk of bladder cancer in the New England bladder cancer study. Int J Cancer 2011, Accessed July 8, 2011. http://www.ncbi.nlm.nih.gov/pubmed/21678399.
59. Bolt H.M., Golka K. The debate on carcinogenicity of permanent hair dyes: New insights. Crit Rev Toxicol 2007, 37:521-536.
60. Wu H., Chen K., Tseng W. Epidemiologic studies on blackfoot disease. I. Prevalence and incidence of the disease by age, sex, year, occupation, and geographical distribution. Memoirs College Med Natl Taiwan Univ 1961, 33-50.
61. Chen C.J., Chuang Y.C., You S.L., et al. A retrospective study on malignant neoplasms of bladder, lung, and liver in blackfoot disease endemic area in Taiwan. Br J Cancer 1986, 53:399-405.
62. Chiang H.S., Guo H.R., Hong C.L., et al. The incidence of bladder cancer in the blackfoot disease endemic area in Taiwan. Br J Urol 1993, 71:274-278.
63. Tan L.-B., Chen K.-T., Guo H.-R. Clinical and epidemiological features of patients with genitourinary tract tumour in a blackfoot disease endemic area of Taiwan. BJU Int 2008, 102:48-54.
64. Bates M.N., Smith A.H., Hopenhayn-Rich C. Arsenic ingestion and internal cancers: A review. Am J Epidemiol 1992, 135:462-476.
65. Hopenhayn-Rich C., Biggs M.L., Fuchs A., et al. Bladder cancer mortality associated with arsenic in drinking water in Argentina. Epidemiology 1996, 7:117-124.
66. Kuo T.L. Arsenic content of artesian well water in endemicarea of chronic arsenic poisoning. Reports of Institute of Pathology 1964, 20:7-13. National Taiwan University College of Medicine, Taipei, Taiwan.
67. Arsenic and Clarifications to Compliance and New Source Contaminants Monitoring Final Rule, Federal Register (66 FR 6976) United States Environmental Protection Agency, Accessed June 28, 2011. http://water.epa.gov/lawsregs/rulesregs/sdwa/arsenic/regulations.cfm.
68. Meliker J.R., Slotnick M.J., AvRuskin G.A., et al. Lifetime exposure to arsenic in drinking water and bladder cancer: A population-based case-control study in Michigan, USA. Cancer Causes Control 2010, 21:745-757.
69. Steinmaus C., Yuan Y., Bates M.N., et al. Case-control study of bladder cancer and drinking water arsenic in the western United States. Am J Epidemiol 2003, 158:1193-1201.
70. Chiou H.Y., Chiou S.T., Hsu Y.H., et al. Incidence of transitional cell carcinoma and arsenic in drinking water: A follow-up study of 8,102 residents in an arseniasis-endemic area in northeastern Taiwan. Am J Epidemiol 2001, 153:411-418.
71. Mink P.J., Alexander D.D., Barraj L.M., et al. Low-level arsenic exposure in drinking water and bladder cancer: A review and meta-analysis. Regul Toxicol Pharmacol 2008, 52:299-310.
72. Tchounwou P.B., Centeno J.A., Patlolla A.K. Arsenic toxicity, mutagenesis, and carcinogenesis-a health risk assessment and management approach. Mol Cell Biochem 2004, 255:47-55.
73. Jomova K., Jenisova Z., Feszterova M., et al. Arsenic: Toxicity, oxidative stress, and human disease. J Appl Toxicol 2011, 31:95-107.
74. IARC monographs on the evaluation of carcinogenic risks to humans. Diesel and gasoline engine exhausts and some nitroarenes. IARC Monogr Eval Carcinog Risks Hum 1989, 46:1-458. International Agency for Research on Cancer.
75. Petersen A., Hansen J., Olsen J.H., et al. Cancer morbidity among Danish male urban bus drivers: A historical cohort study. Am J Ind Med 2010, 53:757-761.
76. Clavel J., Mandereau L., Limasset J.C., et al. Occupational exposure to polycyclic aromatic hydrocarbons and the risk of bladder cancer: A French case-control study. Int J Epidemiol 1994, 23:1145-1153.
77. Bosetti C., Boffetta P., La Vecchia C. Occupational exposures to polycyclic aromatic hydrocarbons, and respiratory and urinary tract cancers: A quantitative review to 2005. Ann Oncol 2007, 18:431-446.
78. Roger Chou T.D. Screening Adults for Bladder Cancer Accessed July 23, 2011. http://www.ncbi.nlm.nih.gov/books/NBK47510/.
79. Straif K., Baan R., Grosse Y., et al. Carcinogenicity of polycyclic aromatic hydrocarbons. Lancet Oncol 2005, 6:931-932.
80. Colli J., Lee B.R., Thomas R. Population densities in relation to bladder cancer mortality rates in America from 1950 to 1994. Int Urol Nephrol 2011, Accessed July 23, 2011. http://www.ncbi.nlm.nih.gov/pubmed/21701802.
81. Lash L.H., Parker J.C. Hepatic and renal toxicities associated with perchloroethylene. Pharmacol Rev 2001, 53:177-208.
82. Dry-cleaning, some chlorinated solvents and other industrial chemicals. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, IARC Monographs, Lyon, France 1995, 63:33-477.
83. Tetrachloroethylene. IARC monographs on the evaluation of carcinogenic risks to humans. Dry cleaning, some chlorinated solvents, and other industrial chemicals 1995, 63:159-221. International Agency for Research on Cancer, IARC, Lyon, b.
84. Mundt K.A., Birk T., Burch M.T. Critical review of the epidemiological literature on occupational exposure to perchloroethylene and cancer. Int Arch Occup Environ Health 2003, 76:473-491.
85. Thompson D.E., Mabuchi K., Ron E., et al. Cancer incidence in atomic bomb survivors. Part II: Solid tumors, 1958-1987. Radiat Res 1994, 137:S17-S67.
86. Brown A.P., Neeley E.S., Werner T., et al. A population-based study of subsequent primary malignancies after endometrial cancer: Genetic, environmental, and treatment-related associations. Int J Radiat Oncol Biol Phys 2010, 78:127-135.
87. Chaturvedi A.K., Engels E.A., Gilbert E.S., et al. Second cancers among 104,760 survivors of cervical cancer: Evaluation of long-term risk. J Natl Cancer Inst 2007, 99:1634-1643.
88. Nieder A.M., Porter M.P., Soloway M.S. Radiation therapy for prostate cancer increases subsequent risk of bladder and rectal cancer: A population based cohort study. J Urol 2008, 180:2005-2009. Discussion 2009-10.
89. Coussens L.M., Werb Z. Inflammation and cancer. Nature 2002, 420:860-867.
90. Michaud D.S. Chronic inflammation and bladder cancer. Urol Oncol 2007, 25:260-268.
91. Rollinson D. A wake up call for urinary schistosomiasis: Reconciling research effort with public health importance. Parasitology 2009, 136:1593-1610.
92. Ferguson A.R. Associated bilharziasis and primary malignant disease of the urinary bladder with observations on a series of forty cases. J Pathol Bacteriol 1911, 16:76-94.
93. Salem S., Mitchell R.E., El-Alim El-Dorey A., et al. Successful control of schistosomiasis and the changing epidemiology of bladder cancer in Egypt. BJU Int 2011, 107:206-211.
94. Cancer Incidence in Four Member Countries (Cyprus, Egypt, Israel, and Jordan) of the Middle East Cancer Consortium (MECC) Compared with US SEER 2006, National Cancer Institute, Bethesda, MD, NIH Pub no. 06-5873. L.S. Freedman, B.K. Edwards, L.A. Ries, J.L. Young (Eds.).
95. Gouda I., Mokhtar N., Bilal D., et al. Bilharziasis and bladder cancer: A time trend analysis of 9843 patients. J Egypt Natl Canc Inst 2007, 19:158-162.
96. Botelho M.C., Oliveira P.A., Lopes C., et al. Urothelial dysplasia and inflammation induced by Schistosoma haematobium total antigen instillation in mice normal urothelium. Urol. Oncol 2009, Accessed July 31, 2011. http://www.ncbi.nlm.nih.gov/pubmed/19945304.
97. Locke J.R., Hill D.E., Walzer Y. Incidence of squamous cell carcinoma in patients with long-term catheter drainage. J Urol 1985, 133:1034-1035.
98. Pannek J. Transitional cell carcinoma in patients with spinal cord injury: A high risk malignancy?. Urology 2002, 59:240-244.
99. Hamid R., Bycroft J., Arya M., et al. Screening cystoscopy and biopsy in patients with neuropathic bladder and chronic suprapubic indwelling catheters: Is it valid?. J Urol 2003, 170:425-427.
100. Moody C.A., Laimins L.A. Human papillomavirus oncoproteins: Pathways to transformation. Nat Rev Cancer 2010, 10:550-560.
101. Noel J.C., Thiry L., Verhest A., et al. Transitional cell carcinoma of the bladder: Evaluation of the role of human papillomaviruses. Urology 1994, 44:671-675.
102. Husain E., Prowse D.M., Ktori E., et al. Human papillomavirus is detected in transitional cell carcinoma arising in renal transplant recipients. Pathology 2009, 41:245-247.
103. Li N., Yang L., Zhang Y., et al. Human papillomavirus infection and bladder cancer risk: A meta-analysis. J Infect Dis 2011, 204:217-223.
104. Gutiérrez J., Jiménez A., de Dios Luna J., et al. Meta-analysis of studies analyzing the relationship between bladder cancer and infection by human papillomavirus. J Urol 2006, 176:2474-2481. Discussion 2481.
105. Buzzeo B.D., Heisey D.M., Messing E.M. Bladder cancer in renal transplant recipients. Urology 1997, 50:525-528.
106. Vajdic C.M., McDonald S.P., McCredie M.R.E., et al. Cancer incidence before and after kidney transplantation. JAMA 2006, 296:2823-2831.
107. Miao Y., Everly J.J., Gross T.G., et al. De novo cancers arising in organ transplant recipients are associated with adverse outcomes compared with the general population. Transplantation 2009, 87:1347-1359.
108. Dietrich K., Schned A., Fortuny J., et al. Glucocorticoid therapy and risk of bladder cancer. Br J Cancer 2009, 101:1316-1320.
109. Worth P.H. Cyclophosphamide and the bladder. Br Med J 1971, 3:182.
110. Pedersen-Bjergaard J., Ersbøll J., Hansen V.L., et al. Carcinoma of the urinary bladder after treatment with cyclophosphamide for non-Hodgkin's lymphoma. N Engl J Med 1988, 318:1028-1032.
111. Brock N., Pohl J., Stekar J., et al. Studies on the urotoxicity of oxazaphosphorine cytostatics and its prevention-III. Profile of action of sodium 2-mercaptoethane sulfonate (mesna). Eur J Cancer Clin Oncol 1982, 18:1377-1387.
112. Travis L.B., Curtis R.E., Glimelius B., et al. Bladder and kidney cancer following cyclophosphamide therapy for non-Hodgkin's lymphoma. J Natl Cancer Inst 1995, 87:524-530.
113. Cox P.J. Cyclophosphamide cystitis-identification of acrolein as the causative agent. Biochem Pharmacol 1979, 28:2045-2049.
114. McCarroll N., Keshava N., Cimino M., et al. An evaluation of the mode of action framework for mutagenic carcinogens case study: Cyclophosphamide. Environ Mol Mutagen 2008, 49:117-131.
115. Bryant B.M., Jarman M., Ford H.T., et al. Prevention of isophosphamide-induced urothelial toxicity with 2-mercaptoethane sulphonate sodium (mesnum) in patients with advanced carcinoma. Lancet 1980, 2:657-659.
116. Hensley M.L., Schuchter L.M., Lindley C., et al. American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants. J Clin Oncol 1999, 17:3333-3355.
117. Johansson S., Angervall L., Bengtsson U., et al. Uroepithelial tumors of the renal pelvis associated with abuse of phenacetin-containing analgesics. Cancer 1974, 33:743-753.
118. Johansson S., Angervall L. Carcinogenicity of phenacetin. Science 1979, 204:130.
119. Fokkens W. Phenacetin abuse related to bladder cancer. Environ Res 1979, 20:192-198.
120. Piper J.M., Tonascia J., Matanoski G.M. Heavy phenacetin use and bladder cancer in women aged 20 to 49 years. N Engl J Med 1985, 313:292-295.
121. Peters J.M., Morishima H., Ward J.M., et al. Role of CYP1A2 in the toxicity of long-term phenacetin feeding in mice. Toxicol Sci 1999, 50:82-89.
122. Fortuny J., Kogevinas M., Zens M.S., et al. Analgesic and anti-inflammatory drug use and risk of bladder cancer: A population based case control study. BMC Urol 2007, 7:13.
123. Fortuny J., Kogevinas M., Garcia-Closas M., et al. Use of analgesics and nonsteroidal anti-inflammatory drugs, genetic predisposition, and bladder cancer risk in Spain. Cancer Epidemiol Biomarkers Prev 2006, 15:1696-1702.
124. Genkinger J.M., De Vivo I., Stampfer M.J., et al. Nonsteroidal anti-inflammatory drug use and risk of bladder cancer in the health professionals follow-up study. Int J Cancer 2007, 120:2221-2225.
125. Lewis J.D., Ferrara A., Peng T., et al. Risk of bladder cancer among diabetic patients treated with pioglitazone: Interim report of a longitudinal cohort study. Diabetes Care 2011, 34:916-922.
126. Drug Safety and Availability - FDA Drug Safety Communication: Update to ongoing safety review of Actos (pioglitazone) and increased risk of bladder cancer Center for Drug Evaluation and Research, Accessed July 31, 2011. http://www.fda.gov/Drugs/DrugSafety/ucm259150.htm.
127. Cosyns J.P., Jadoul M., Squifflet J.P., et al. Urothelial lesions in Chinese-herb nephropathy. Am J Kidney Dis 1999, 33:1011-1017.
128. Nortier J.L., Martinez M.C., Schmeiser H.H., et al. Urothelial carcinoma associated with the use of a Chinese herb (Aristolochia fangchi). N Engl J Med 2000, 342:1686-1692.
129. Reuber M.D. Carcinogenicity of saccharin. Environ Health Perspect 1978, 25:173-200.
130. Takayama S., Sieber S.M., Adamson R.H., et al. Long-term feeding of sodium saccharin to nonhuman primates: Implications for urinary tract cancer. J Natl Cancer Inst 1998, 90:19-25.
131. Cohen S.M., Arnold L.L., Cano M., et al. Calcium phosphate-containing precipitate and the carcinogenicity of sodium salts in rats. Carcinogenesis 2000, 21:783-792.
132. Weihrauch M.R., Diehl V. Artificial sweeteners-do they bear a carcinogenic risk?. Ann Oncol 2004, 15:1460-1465.
133. Chiu H.-F., Tsai S.-S., Yang C.-Y. Nitrate in drinking water and risk of death from bladder cancer: An ecological case-control study in Taiwan. J Toxicol Environ Health Part A 2007, 70:1000-1004.
134. Ward M.H., Cantor K.P., Riley D., et al. Nitrate in public water supplies and risk of bladder cancer. Epidemiology 2003, 14:183-190.
135. Zeegers M.P., Selen R.F.M., Kleinjans J.C.S., et al. Nitrate intake does not influence bladder cancer risk: The Netherlands cohort study. Environ Health Perspect 2006, 114:1527-1531.
136. Ferrucci L.M., Sinha R., Ward M.H., et al. Meat and components of meat and the risk of bladder cancer in the NIH-AARP Diet and Health Study. Cancer 2010, 116:4345-4353.
137. Chlorinated Drinking Water; Chlorination By-Products. IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Humans 1991, Vol 52. International Agency for Research on Cancer, International Agency for Research on Cancer, Lyon, France.
138. Disinfectant and Disinfectant Byproducts. Environmental Health Criteria 216 2000, International Programme on chemical safety (IPCS), United Nations Environment Programme (UNEP); International Labour Organization (ILO); World Health Organization (WHO), Geneva.
139. Villanueva C.M., Cantor K.P., Cordier S., et al. Disinfection byproducts and bladder cancer: A pooled analysis. Epidemiology 2004, 15:357-367.
140. Costet N., Villanueva C.M., Jaakkola J.J.K., et al. Water disinfection by-products and bladder cancer: Is there a European specificity?. A pooled and meta-analysis of European case-control studies. Occup Environ Med 2011, 68:379-385.
141. Garland C.F., Garland F.C. Do sunlight and vitamin D reduce the likelihood of colon cancer?. Int J Epidemiol 1980, 9:227-231.
142. Garland C., Shekelle R.B., Barrett-Connor E., et al. Dietary vitamin D and calcium and risk of colorectal cancer: A 19-year prospective study in men. Lancet 1985, 1:307-309.
143. Mondul A.M., Weinstein S.J., Männistö S., et al. Serum vitamin D and risk of bladder cancer. Cancer Res 2010, 70:9218-9223.
144. Brinkman M.T., Karagas M.R., Zens M.S., et al. Minerals and vitamins and the risk of bladder cancer: Results from the New Hampshire Study. Cancer Causes Control 2010, 21:609-619.
145. Mohr S.B., Garland C.F., Gorham E.D., et al. Ultraviolet B irradiance and incidence rates of bladder cancer in 174 countries. Am J Prev Med 2010, 38:296-302.
146. Chen W., Clements M., Rahman B., et al. Relationship between cancer mortality/incidence and ambient ultraviolet B irradiance in China. Cancer Causes Control 2010, 21:1701-1709.
147. Nieder A.M., Mackinnon J.A., Huang Y., et al. Florida bladder cancer trends 1981 to 2004: Minimal progress in decreasing advanced disease. J Urol 2008, 179:491-495. Discussion 495.
148. Resseguie L.J., Nobrega F.T., Farrow G.M., et al. Epidemiology of renal and ureteral cancer in Rochester, Minnesota, 1950-1974, with special reference to clinical and pathologic features. Mayo Clin Proc 1978, 53:503-510.
149. Botteman M.F., Pashos C.L., Redaelli A., et al. The health economics of bladder cancer: A comprehensive review of the published literature. Pharmacoeconomics 2003, 21:1315-1330.
150. Nelson A. Unequal treatment: Confronting racial and ethnic disparities in health care. J Natl Med Assoc 2002, 94:666-668.
151. Scosyrev E., Noyes K., Feng C., et al. Sex and racial differences in bladder cancer presentation and mortality in the US. Cancer 2009, 115:68-74.
152. Risch A., Wallace D.M., Bathers S., et al. Slow N-acetylation genotype is a susceptibility factor in occupational and smoking related bladder cancer. Hum Mol Genet 1995, 4:231-236.
153. Blot W.J., Fraumeni J.F. Geographic patterns of bladder cancer in the United States. J Natl Cancer Inst 1978, 61:1017-1023.
154. Nieder A.M., MacKinnon J.A., Fleming L.E., et al. Bladder cancer clusters in Florida: Identifying populations at risk. J Urol 2009, 182:46-50. Discussion 51.
155. Boulos D.N.K., Ghali R.R., Ibrahim E.M., et al. An 8-year snapshot of geospatial cancer research (2002-2009): Clinico-epidemiological and methodological findings and trends. Med Oncol 2010, Accessed August 15, 2011. http://www.ncbi.nlm.nih.gov/pubmed/20589539.
156. Langholz B., Thomas D., Xiang A., et al. Latency analysis in epidemiologic studies of occupational exposures: Application to the Colorado Plateau uranium miners cohort. Am J Ind Med 1999, 35:246-256.